Straumann Group's Strong First Half Performance and 2025 Outlook

Straumann Group reported robust results for the first half of 2025, with revenue reaching CHF 1.3 billion, marking a 10.2% organic growth. Despite unfavorable currency developments, the core EBIT margin stood at 26.6%, or 27.3% at constant 2024 currency rates. New product launches contributed significantly to this growth, with the iEXCEL system gaining traction in Europe.

The Shanghai campus in China has started producing Straumann implants, further enhancing the Group's manufacturing network. Despite the challenges from currency fluctuations, the Group remains confident in achieving organic revenue growth in the high single-digit percentage range for 2025, with improvements in core EBIT margin.

Regional performance was strong across EMEA, APAC, and LATAM, with a stable growth rate in North America. Digital innovation continues to drive growth, emphasized by advancements like the Straumann AXS platform and the successful introduction of the MIDAS 3D printer.